Humacyte (HUMA) CEO addresses concerns in NYT over FDA approval of Symvess

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/3/2026

1. PANW
2. GTLB
3. MDB
4. DELL
5. VRTS
6. GOOGL
7. SPY
8. HPE
9. SNOW
10. USO

Go back to Humacyte (HUMA) CEO addresses concerns in NYT over FDA approval of Symvess
(NASDAQ: HUMA) Delayed: 0.60 +0.03 (5.26%)
Previous Close $0.57    52 Week High $ 
Open $0.57    52 Week Low $ 
Day High $0.61    P/E N/A 
Day Low $0.57    EPS $ 
Volume 5,178,324